B.R.A.I.N. Biotechnology Research And Information Network AG: Annual General Meeting for Fiscal Year 2018/2019

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): AGM/EGM
05.03.2020 / 16:23
The issuer is solely responsible for the content of this announcement.

BRAIN AG: Annual General Meeting for Fiscal Year 2018/2019

• Discharge of the Management Board and Supervisory Board
• Dr. Georg Kellinghusen re-elected to the Supervisory Board

Zwingenberg, Germany
05 March 2020

At today's Annual General Meeting of BRAIN AG, 12,644,750 of the total share capital, which is divided into 18,055,782 shares, was represented when the vote was taken. The attendance, based on the share capital, was thus 70,03%.

With the exception of one item, the remaining items on the agenda were accepted by the participating shareholders. The resolution on granting a new authorization to issue convertible bonds and / or bonds with warrants was not adopted.

Adriaan Moelker (CEO, BRAIN AG), in his first speech as Chairman of the Board, pointed out: "BRAIN is a great company with a great future. I see very good opportunities to significantly increase revenues and reduce losses in the coming years. We can achieve this by better exploiting existing potential in the enzyme business, further internationalizing the business and focusing the project portfolio more strongly."

Manfred Bender, CFO on the BRAIN AG Management Board, presented the figures for the past financial year and said: "We have clearly achieved our goal of double-digit growth. This is a remarkable development in the general economic environment."

Changes in the Supervisory Board

A new Supervisory Board member of BRAIN AG had to be elected at the Annual General Meeting, as the term of office of the Chairman of the Supervisory Board, Dr. Georg Kellinghusen, ended as planned at the end of the Annual General Meeting. Dr. Kellinghusen was re-elected to the Supervisory Board by a large majority and will again stand for election as Chairman at its constitutive meeting.

Two other Supervisory Board members, Dr. Martin B. Jager and Dr. Rainer Marquart, had left the Supervisory Board prematurely. The Company intends to appoint two new members to the Supervisory Board in accordance with section 104(2) of the German Stock Corporation Act (AktG), so that the Supervisory Board will again consist of six members in future.

On behalf of the company, Dr. Georg Kellinghusen, the Chairman of the Supervisory Board who presided over the Annual General Meeting, thanked the two departing Supervisory Board members for their commitment.

The detailed voting results as well as the presentation of the Management Board and all other documents relating to the Annual General Meeting are available on the BRAIN AG website at https://www.brain-biotech.com/investors/annual-general-meetings.

Further information

Annual Report 2018/19:
https://www.brain-biotech.com/investors/financial-publications/2018-19

Financial calendar:
www.brain-biotech.com/investors/financial-calendar


About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN's business model is based on two pillars. The BioScience segment comprises mainly of the research and development business with industrial partners (the "Tailor-Made Solutions" cooperation business), and the company's own research and development. The BioIndustrial segment consists mainly of the industrially scalable products business. Further information is available at www.brain-biotech.com.

B.R.A.I.N.
Biotechnology Research
And Information Network AG
Darmstädter Str. 34-36
64673 Zwingenberg
Germany
www.brain-biotech.com

Contact Investor Relations
Martina Schuster
Tel.: +49-6251-9331-69
E-Mail IR: ir@brain-biotech.com

Media Contact
Dr. Stephanie Konle
Managing Associate Corporate Communications
Phone +49-(0)-6251-9331-70
Email: stk@brain-biotech.com

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.
 

Follow BRAIN AG on Twitter (Twitter@BRAINbiotech) and LinkedIn (@BRAIN AG)

05.03.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de